EUCTR2018-005086-39-HU进行中（未招募）1 期
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacyand Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis
andos Biopharma Inc.0 个研究点目标入组 195 人开始时间: 2019年4月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Male and female subjects aged 18 to 75 years, inclusive.
- •2) Diagnosis of UC for at least 3 months prior to screening.
- •3) Mild to moderate UC, as defined by a total Mayo Score of 4 to 10 inclusive at baseline with a MES = 2 (confirmed by central reader).
- •4) If subjects have previously received biologic therapy for UC (i.e.,TNF, tumor necrosis factor [TNF] antagonists, vedolizumab or ustekinumab), they must have a washout period of 8 weeks prior to randomization, and any previous failure of biologic treatment is limited to only one class of biologic. (Note: this inclusion criterion is only applicable until 58 subjects with prior exposure to biologic therapy have been randomized).
- •5) If subjects are receiving the following UC treatments, they must be on a stable dose for at least 1 month prior to randomization: 5-aminosalicylates (5-ASAs) (not exceeding 4.8 g per day), oral corticosteroids (not exceeding prednisone 20 mg, budesonide 9 mg, or equivalent).
- •6) If subjects are receiving bile-salt sequestrant, they must be on a stable dose for at least 3 months prior to randomization.
- •7) If subjects are receiving any nonprohibited medications, they must agree to maintain stable doses of concomitant medications for UC for the duration of the trial.
- •8) Unlikely to conceive, as defined by 1 of the following: a) subject is surgically sterilized female, b) subject is postmenopausal female = 45 years of age with clinical documentation of menopause (i.e., 12 months without menses), or c) subject is male or subject is woman of child bearing potential (WOCBP), and agrees to abstain from heterosexual activity, use adequate hormonal contraception, or use double barrier contraception.
- •9) For WOCBP, the subject must have a negative pregnancy test at screening and within 24 hours prior to the first dose of study drug.
- •10) Able to participate fully in all aspects of this clinical trial.
- •11) Written informed consent must be obtained and documented.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 185
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1) A diagnosis of CD, indeterminate colitis, or presence or history of fistula with CD.
- •2) Severe UC as per modified Truelove and Witts criteria (= 6 bloody stools per day and one or more of the following: pulse > 90 bpm, temperature > 37.8°C, hemoglobin < 10.5 g/dl, or high sensitivity C-reactive protein (hs CRP) > 30 mg/l.
- •3) Disease activity limited to distal 15 cm (proctitis).
- •4) Treatment with immunosuppressant (azathioprine, 6-mercaptopurine [6-MP]) within 25 days prior to randomization.
- •5) History of toxic megacolon, abdominal abscess, symptomatic colonic stricture, or stoma; history or is at imminent risk of colectomy.
- •6) History or current evidence of colonic dysplasia or adenomatous colonic polyps.
- •7) Current bacterial or parasitic pathogenic enteric infection, including Clostridium difficile, known infection with hepatitis B or C virus, known infection with human immunodeficiency virus, infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection within 6 months prior to screening, any infection requiring antimicrobial therapy within 2 weeks prior to screening, history of more than 1 episode of herpes zoster or any episode of disseminated zoster.
- •8) Live virus vaccination within 1 month prior to screening.
- •9) Treatment with cyclosporine, mycophenolate, tacrolimus, or tofacitinib within 4 weeks prior to randomization.
- •10) Treatment with intravenous corticosteroids, rectal corticosteroids, or rectal 5-ASA within 2 weeks prior to randomization.
- •11) Fecal microbiota transplantation within 1 month prior to screening.
- •12) A concurrent clinically significant, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, GI, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, might confound the study results or poses additional risk to the subject.
- •13) Known primary or secondary immunodeficiency.
- •14) History of myocardial infarction, unstable angina, transient ischemic attack, decompensated heart failure requiring hospitalization, congestive heart failure (New York Health Association [NYHA] Class 3 or 4), uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6 months of screening.
- •15) Clinically meaningful laboratory abnormalities at screening, as determined and documented by the investigator.
- •16) Pregnant or lactating females.
- •17) Any surgical procedure requiring general anesthesia within 1 month prior to screening, or planned elective surgery during the study.
- •18) History of malignant neoplasms or carcinoma in situ within 5 years prior to screening.
- •19) Current or recent history of alcohol dependence or illicit drug use that in the opinion of the investigator may interfere with the subject’s ability to comply with the study procedures.
- •20) Mental or legal incapacitation at the time of screening visit or a history of clinically significant psychiatric disorders that would impact the ability to participate in the trial according to the investigator.
- •21) Unable to attend study visits or comply with procedures.
- •22) Concurrent participation in any other interventional study.
- •23) Received any investigational therapy within 30 days of initiation of study drug.
- •24) Serious underlying disease other than UC that in the opinion of the investigator may interfere with the subject’s ability to participate fully in the study.
- •25) Previous ex
研究者
相似试验
进行中（未招募）
不适用
Clinical research study to evaluate safety and efficacy of alpha1-proteinase inhibitor (A1-PI) compared to placebo (a product that does not contain the active ingredient) administered intravenously to patients with deficiency of alpha1-proteinase inhibitor and emphysemaEUCTR2005-003459-12-SECSL Behring GmbH180
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of BT-11 product oral tablets in Mild to Moderate Ulcerative ColitisMild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifestations: ulcerative colitis (UC) and Crohn’s disease (CD). UC manifests through complex interactions between the gut microbiome, dysregulated immune responses, genetic mutations, diet, and other environmental factors.MedDRA version: 20.0Level: PTClassification code 10009900Term: Colitis ulcerativeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-005086-39-PLandos Biopharma Inc.195
进行中（未招募）
1 期
A clinical study investigating OM-85 efficacy and safety in children suffering from Recurrent WheezingRecurrent wheezingMedDRA version: 21.1Level: LLTClassification code: 10066689Term: Chronic wheezing Class: 10038738CTIS2024-511083-90-00OM Pharma SA288
进行中（未招募）
不适用
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to compare the Efficacy and Safety of 60 mg/kg body weight of Zemaira® weekly i.v. administration with Placebo weekly i.v. administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due to Alpha1-Proteinase Inhibitor Deficiency - N/AChronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.MedDRA version: 8.0Level: LLTClassification code 10001811EUCTR2005-003459-12-BGCSL Behring GmbH100
已完成
2 期
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects with Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects with Active Rheumatoid Arthritis.NL-OMON52687Bristol-Myers Squibb6